☆ 4.6 Article

Biomarkers of Neurological Damage: From Acute Stage to Post-Acute Sequelae of COVID-19

CELLS (2023)

Related references

Note: Only part of the references are listed.

Review Chemistry, Medicinal

Clinical Utility of Soluble CD163 and its Diagnostic and Prognostic Value in a Variety of Neurological Disorders

Maryam Rezaee et al.

Summary: Nowadays, there is a need for new biomarkers and therapeutic strategies for the treatment of Neurological Diseases, particularly neurodegenerative diseases. Soluble CD163 (sCD163) has been identified as a potential biomarker for these diseases, as its levels increase in biofluids during inflammation and activation of macrophage/microglia. sCD163 can also serve as a modulator of adaptive immune suppression after stroke.

MINI-REVIEWS IN MEDICINAL CHEMISTRY (2023)

Add to Collection

Article Pharmacology & Pharmacy

An MMP-9 exclusive neutralizing antibody attenuates blood-brain barrier breakdown in mice with stroke and reduces stroke patient-derived MMP-9 activity

Yabin Ji et al.

Summary: A human IgG monoclonal antibody called L13 showed potential as a therapeutic approach for both ischemic and hemorrhagic stroke by selectively inhibiting MMP-9 activity and reducing brain tissue injury. Treatment with L13 improved neurological outcomes and attenuated BBB breakdown in mouse stroke models. The antibody also neutralized MMP-9 activity in stroke patients' sera and brain tissues, suggesting its clinical application.

PHARMACOLOGICAL RESEARCH (2023)

Add to Collection

Review Cell Biology

Role of SARS-CoV-2 Spike-Protein-Induced Activation of Microglia and Mast Cells in the Pathogenesis of Neuro-COVID

Theoharis C. Theoharides et al.

Summary: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19, and approximately 45% of patients experience long-term fatigue and neurovascular inflammation. The spike protein of SARS-CoV-2 can disrupt the blood-brain barrier, damage neurons, and activate brain mast cells and microglia, resulting in the release of neuroinflammatory molecules. Recent evidence suggests that the flavanol eriodictyol, along with oleuropein and sulforaphane, may be effective in treating COVID-19 and its long-term consequences.

CELLS (2023)

Add to Collection

Review Cell Biology

Pathogenesis Underlying Neurological Manifestations of Long COVID Syndrome and Potential Therapeutics

Albert Leng et al.

Summary: The development of long-term symptoms of COVID-19, known as long COVID or PASC, can involve persistent neurological complications in up to one third of patients. These complications include fatigue, brain fog, headaches, cognitive impairment, and neuropsychiatric symptoms. The underlying pathological mechanisms behind these symptoms are still unclear, but hypotheses suggest involvement of nervous system and systemic factors such as viral persistence, abnormal immune response, and endothelial dysfunction. Current therapeutic approaches focus on antivirals, inflammation reduction, and olfactory epithelium regeneration.

CELLS (2023)

Add to Collection

Article Cell Biology

COVID-19 Affects Serum Brain-Derived Neurotrophic Factor and Neurofilament Light Chain in Aged Men: Implications for Morbidity and Mortality

Carla Petrella et al.

Summary: This pilot study aimed to investigate the impact of COVID-19 on brain-derived neurotrophic factor (BDNF), matrix metalloproteinases (MMP) 2 and 9, and neurofilament light chain (NFL) pathways in aged men. The results showed disrupted serum BDNF, NFL, and MMP-2 presence in severe or fatal COVID-19 cases, along with changes in routine blood parameters. The ratio of MMPs (2 and 9) to BDNF and NFL was found to be a useful tool for predicting fatal outcomes of COVID-19.

CELLS (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Tissue Inhibitor of Matrix Metalloproteinases-1 (TIMP-1) and Pulmonary Involvement in COVID-19 Pneumonia

Maria Antonella Zingaropoli et al.

Summary: The study aimed to evaluate the association between MMP-2, MMP-9, TIMP-1 and chest radiological findings in COVID-19 patients. The results showed that COVID-19 patients had higher plasma levels of MMP-9 and TIMP-1 compared to healthy donors, and the ARDS group had higher levels of MMP-9 and TIMP-1 and the activity of MMP-2 and MMP-9 compared to the non-ARDS group. There was a positive correlation between TIMP-1 levels and chest CT scores. After three months of discharge, TIMP-1 levels decreased while MMP-9 levels increased.

BIOMOLECULES (2023)

Add to Collection

Review Clinical Neurology

Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis

Lavienraj Premraj et al.

Summary: Neurological and neuropsychiatric symptoms that persist or develop three months after the onset of COVID-19 pose a significant threat to the global healthcare system. A systematic review analyzed data from multiple studies and found that fatigue, cognitive dysfunction, and sleep disturbances were key features of post-COVID-19 syndrome. Psychiatric manifestations such as anxiety and depression were also common and increased in prevalence over time.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2022)

Add to Collection

Article Immunology

Role of Tocilizumab in Down Regulating sCD163 Plasmatic Levels in a Cohort of COVID-19 Patients

Raffaella Marocco et al.

Summary: This study investigated the effect of tocilizumab on sCD163 plasma levels in COVID-19 patients. The results showed that sCD163 plasma levels were elevated in COVID-19 patients and tocilizumab treatment efficiently down-regulated these levels, regardless of the clinical outcome.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Cell Biology

Neuro-Axonal Damage and Alteration of Blood-Brain Barrier Integrity in COVID-19 Patients

Maria Antonella Zingaropoli et al.

Summary: Neurofilament light chain levels were higher in COVID-19 patients with severe neurological symptoms, especially those with acute respiratory distress syndrome (ARDS). Neuro-COVID patients with ARDS showed higher levels of neurofilament light chain and matrix metalloproteinases in cerebrospinal fluid. The presence of SARS-CoV-2 RNA did not correlate with increased neurofilament light chain or matrix metalloproteinase levels. ARDS in COVID-19 patients may be associated with central nervous system damage and blood-brain barrier disruption.

CELLS (2022)

Add to Collection

Article Medicine, General & Internal

Multivariate profile and acute-phase correlates of cognitive deficits in a COVID-19 hospitalised cohort

Adam Hampshire et al.

Summary: This study found that survivors of severe COVID-19 experience persistent cognitive deficits, which are most strongly related to the severity of acute illness. These cognitive deficits primarily affect higher cognitive functions and processing speed.

ECLINICALMEDICINE (2022)

Add to Collection

Article Clinical Neurology

Serum Neurofilament Light Chain Levels in the Intensive Care Unit: Comparison between Severely Ill Patients with and without Coronavirus Disease 2019

Raoul Sutter et al.

Summary: There is increasing evidence for various neurological manifestations of COVID-19, with higher sNfL concentrations observed in critically ill patients with COVID-19 compared to healthy controls and critically ill non-COVID-19 patients. Elevated sNfL levels were associated with unfavorable short-term outcomes, indicating common and pronounced neuronal injury in critically ill patients.

ANNALS OF NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID-19 and associated with neurological symptoms and disease severity

Johan Virhammar et al.

Summary: This study analyzed CSF biomarkers of CNS injury in 19 patients with neurological symptoms of COVID-19, finding elevated levels of NfL protein, GFAp, and total tau. NfL protein was found to be associated with central neurological symptoms and disease severity in these patients.

EUROPEAN JOURNAL OF NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Soluble CD163 Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease

Sara Konstantin Nissen et al.

Summary: This study found that sCD163 in the CSF of PD patients correlated with PD biomarkers and cognition scores, supporting monocyte involvement in neurodegeneration and cognition in PD. An increase in CSF-sCD163 in female patients suggested a sex-distinctive monocyte response. In vitro studies showed the potential connection between CD163 and alpha-synuclein, indicating a role for monocytes in both peripheral and brain immune responses to PD.

MOVEMENT DISORDERS (2021)

Add to Collection

Editorial Material Clinical Neurology

Neurological infection with SARS-CoV-2-the story so far

Tom Solomon

NATURE REVIEWS NEUROLOGY (2021)

Add to Collection

Article Immunology

Matrix metalloproteinases are involved in the development of neurological complications in patients with Coronavirus disease 2019

Mina Mohammadhosayni et al.

Summary: The study found that in COVID-19 patients, the frequency of monocytes in CSF samples of patients with neurological syndrome increased, along with significantly elevated levels of inflammatory cytokines and chemokines. Higher levels of MMPs in CSF samples in NS patients may lead to disruption of BCSFB.

INTERNATIONAL IMMUNOPHARMACOLOGY (2021)

Add to Collection

Article Immunology

Brain injury, endothelial injury and inflammatory markers are elevated and express sex-specific alterations after COVID-19

Jude Savarraj et al.

Summary: COVID-19 can cause brain and endothelial injury, with men showing higher levels of injury markers and inflammatory markers compared to women. Elevated levels of BIMs, CCs, and EIMs in COVID-19 patients suggest brain and endothelial injury, with men being more susceptible to risk factors than women.

JOURNAL OF NEUROINFLAMMATION (2021)

Add to Collection

Article Immunology

Increased sCD163 and sCD14 Plasmatic Levels and Depletion of Peripheral Blood Pro-Inflammatory Monocytes, Myeloid and Plasmacytoid Dendritic Cells in Patients With Severe COVID-19 Pneumonia

Maria Antonella Zingaropoli et al.

Summary: Elevated levels of sCD163 and sCD14 were observed in COVID-19 patients, particularly in those developing ARDS, with correlations to typical inflammatory markers. This suggests their potential use in assessing disease progression risk. Lower percentages of monocytes and DCs in COVID-19 patients, especially in the ARDS group, indicate their role in disease severity.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Dynamic alterations in monocyte numbers, subset frequencies and activation markers in acute and convalescent COVID-19 individuals

Anuradha Rajamanickam et al.

Summary: The study showed dynamic alterations in monocyte counts, subset frequencies, and activation status in acute and convalescent COVID-19 individuals. Patients with severe disease exhibited higher levels of monocyte counts, classical monocyte frequencies, and plasma markers compared to those with mild disease.

SCIENTIFIC REPORTS (2021)

Add to Collection

Review Clinical Neurology

Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis

Ahmed Yassin et al.

Summary: Neurological involvement is common in COVID-19 patients, and early recognition and vigilance of such involvement might impact their overall outcomes.

BMC NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

COVID-19 neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital

Kiran T. Thakur et al.

Summary: Many patients with SARS-CoV-2 infection exhibit neurological signs and symptoms, but autopsy results show that most brains have low levels of detectable virus and it does not correlate with the histopathological alterations.

BRAIN (2021)

Add to Collection

Article Clinical Neurology

Circulating Soluble CD163: A Potential Predictor for the Functional Outcome of Acute Ischemic Stroke

Houchao Sun et al.

Summary: The study found that circulating sCD163 levels were significantly higher in patients with acute ischemic stroke compared to healthy controls, and patients with higher sCD163 concentrations had better functional outcomes. Plasma sCD163 levels were positively correlated with NIHSS scores and infarction volume at baseline, and improvements in NIHSS scores, while negatively associated with the risk of poor functional outcomes.

FRONTIERS IN NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Blood neurofilament light concentration at admittance: a potential prognostic marker in COVID-19

Anne Hege Aamodt et al.

Summary: Elevated concentrations of NfL and GFAp in COVID-19 patients upon admission may indicate increased mortality risk, and these biomarker concentrations are associated with clinical outcomes.

JOURNAL OF NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Serum neurofilament light chain (sNfL) values in a large cross-sectional population of children with asymptomatic to moderate COVID-19

Tobias Geis et al.

Summary: A study on children with asymptomatic to moderate COVID-19 infection showed that a percentage of them had neurological symptoms, but overall, there was no evidence of neuronal damage based on sNfL levels.

JOURNAL OF NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Blood neurofilament light chain and total tau levels at admission predict death in COVID-19 patients

Rebecca De Lorenzo et al.

Summary: The study investigated the clinical prognostic value of markers of neural tissue damage in predicting survival or transfer to ICU in patients infected with COVID-19. Results showed that certain markers were significantly increased in patients with fatal outcomes or needing ICU transfer, with total tau levels accurately predicting mortality. Blood neural markers may offer additional prognostic value for predicting COVID-19 outcomes.

JOURNAL OF NEUROLOGY (2021)

Add to Collection

Letter Clinical Neurology

Neurofilament Light Chain in Patients with COVID-19 and Bacterial Pneumonia

Ha-Yeun Chung et al.

ANNALS OF NEUROLOGY (2021)

Add to Collection

Article Immunology

Neurological symptoms and axonal damage in COVID-19 survivors: are there sequelae?

Silvia Bozzetti et al.

Summary: The persistence of neurological symptoms and late axonal damage after SARS-CoV-2 infection is still unknown. The study found that a significant number of COVID-19 patients still experienced neurological symptoms during follow-up, with hyposmia, fatigue, myalgia, and impaired memory being the most common. Serum neurofilament light chain levels were not able to differentiate patients with or without persistent neurological symptoms, but there was a significant decrease in levels during follow-up. The study suggests that COVID-19 survivors do not show active axonal damage, which is a unique feature of acute SARS-CoV-2 infection.

IMMUNOLOGIC RESEARCH (2021)

Add to Collection

Editorial Material Critical Care Medicine

Neurological complications of COVID-19

Virginia F. J. Newcombe et al.

INTENSIVE CARE MEDICINE (2021)

Add to Collection

Article Clinical Neurology

Cerebrospinal fluid in COVID-19 neurological complications: Neuroaxonal damage, anti-SARS-Cov2 antibodies but no evidence of cytokine storm

Maria A. Garcia et al.

Summary: The study found no obvious neuroinflammatory changes in the CSF of COVID-19 patients and no detection of SARS-CoV2 RNA, which does not support the neurovirulence of SARS-CoV2 or the role of neuroinflammation in the pathogenesis of neurological complications in COVID-19. Anti-SARS-CoV2 antibodies were present in the CSF of some critical COVID-19 patients, but the role of these antibodies and the mechanisms of neuronal damage remain unclear.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2021)

Add to Collection

Article Clinical Neurology

Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease

Whitley W. Aamodt et al.

Summary: The study found that neurofilament light chain protein (NfL) is associated with cognitive function in Parkinson's disease (PD) patients and can predict future cognitive decline. Plasma NfL was identified as a useful prognostic biomarker for PD, predicting the likelihood of PD patients converting to mild cognitive impairment or dementia.

MOVEMENT DISORDERS (2021)

Add to Collection

Article Medicine, General & Internal

Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up

Nelly Kanberg et al.

Summary: Plasma biomarkers of CNS injury were significantly elevated in severe COVID-19 cases during the acute phase but normalized after six months, indicating that neurological sequelae post COVID-19 are not associated with ongoing CNS injury. Despite this normalization, a considerable number of patients reported persistent neurological symptoms, suggesting that additional factors beyond CNS injury biomarkers may contribute to long-term neurological effects of COVID-19.

EBIOMEDICINE (2021)

Add to Collection

Review Clinical Neurology

Potential Neurologic Manifestations of COVID-19

Anna S. Nordvig et al.

Summary: Neurologic complications are increasingly recognized in the COVID-19 pandemic caused by SARS-CoV-2, with potential symptoms including headache, fatigue, dizziness, anosmia, ageusia, anorexia, myalgias, and more. Understanding the neurologic implications of COVID-19 can aid in recognizing and managing neurologic morbidity during and post the 2020 pandemic.

NEUROLOGY-CLINICAL PRACTICE (2021)

Add to Collection

Article Infectious Diseases

A first case of meningitis/encephalitis associated with SARS-Coronavirus-2

Takeshi Moriguchi et al.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)

Add to Collection

Article Clinical Neurology

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China

Ling Mao et al.

JAMA NEUROLOGY (2020)

Add to Collection

Letter Medicine, General & Internal

Neurologic Features in Severe SARS-CoV-2 Infection

Julie Helms et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Review Medicine, General & Internal

Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19) A Review

W. Joost Wiersinga et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Letter Clinical Neurology

Association of neuronal injury blood marker neurofilament light chain with mild-to-moderate COVID-19

Markus Ameres et al.

JOURNAL OF NEUROLOGY (2020)

Add to Collection

Review Clinical Neurology

Neurological associations of COVID-19

Mark A. Ellul et al.

LANCET NEUROLOGY (2020)

Add to Collection

Article Clinical Neurology

Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19

Nelly Kanberg et al.

NEUROLOGY (2020)

Add to Collection

Article Immunology

Increased Serum Levels of sCD14 and sCD163 Indicate a Preponderant Role for Monocytes in COVID-19 Immunopathology

Jose Gomez-Rial et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Clinical Neurology

Frequent neurologic manifestations and encephalopathy-associated morbidity in Covid-19 patients

Eric M. Liotta et al.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2020)

Add to Collection

Editorial Material Clinical Neurology

Peripheral blood neurofilament light chain levels: the neurologist's C-reactive protein?

Gavin Giovannoni

BRAIN (2018)

Add to Collection

Review Clinical Neurology

Looking for novel, brain-derived, peripheral biomarkers of neurological disorders

Natalia Chmielewska et al.

NEUROLOGIA I NEUROCHIRURGIA POLSKA (2018)

Add to Collection

Review Immunology

Reactive Astrocytes: Production, Function, and Therapeutic Potential

Shane A. Liddelow et al.

IMMUNITY (2017)

Add to Collection

Article Biotechnology & Applied Microbiology

Hypoxia Response Element-Regulated MMP-9 Promotes Neurological Recovery via Glial Scar Degradation and Angiogenesis in Delayed Stroke

Hongxia Cai et al.

MOLECULAR THERAPY (2017)

Add to Collection

Review Endocrinology & Metabolism

Matrix metalloproteinases in the brain and blood-brain barrier: Versatile breakers and makers

Ralf G. Rempe et al.

JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2016)

Add to Collection

Review Clinical Neurology

Fluid biomarkers for mild traumatic brain injury and related conditions

Henrik Zetterberg et al.

NATURE REVIEWS NEUROLOGY (2016)

Add to Collection

Review Medicine, General & Internal

Current status of biomarker research in neurology

Jiri Polivka et al.

EPMA JOURNAL (2016)

Add to Collection

Review Neurosciences

Molecular mechanisms linking neuroinflammation and neurodegeneration in MS

Erik Ellwardt et al.

EXPERIMENTAL NEUROLOGY (2014)

Add to Collection

Article Medicine, General & Internal

Glial Scar Formation Occurs in the Human Brain after Ischemic Stroke

Lijie Huang et al.

INTERNATIONAL JOURNAL OF MEDICAL SCIENCES (2014)

Add to Collection

Article Biochemistry & Molecular Biology

Structural Basis for Inflammation-driven Shedding of CD163 Ectodomain and Tumor Necrosis Factor-α in Macrophages

Anders Etzerodt et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2014)

Add to Collection

Article Multidisciplinary Sciences

Soluble CD163 as a Marker of Macrophage Activity in Newly Diagnosed Patients with Multiple Sclerosis

Morten Stilund et al.

PLOS ONE (2014)

Add to Collection

Article Neurosciences

Glial Scar Borders Are Formed by Newly Proliferated, Elongated Astrocytes That Interact to Corral Inflammatory and Fibrotic Cells via STAT3-Dependent Mechanisms after Spinal Cord Injury

Ina B. Wanner et al.

JOURNAL OF NEUROSCIENCE (2013)

Add to Collection

Article Biochemistry & Molecular Biology

The intrathecal CD163-haptoglobin-hemoglobin scavenging system in subarachnoid hemorrhage

James Galea et al.

JOURNAL OF NEUROCHEMISTRY (2012)

Add to Collection

Article Immunology

Soluble CD163 Made by Monocyte/Macrophages Is a Novel Marker of HIV Activity in Early and Chronic Infection Prior to and After Antiretroviral Therapy

Tricia H. Burdo et al.

JOURNAL OF INFECTIOUS DISEASES (2011)

Add to Collection

Article Cell Biology

Tumor necrosis factor α-converting enzyme (TACE/ADAM17) mediates ectodomain shedding of the scavenger receptor CD163

Anders Etzerodt et al.

JOURNAL OF LEUKOCYTE BIOLOGY (2010)

Add to Collection

Review Clinical Neurology

Astroglial Proteins as Diagnostic Markers of Acute Intracerebral Hemorrhage-Pathophysiological Background and Clinical Findings

Robert Brunkhorst et al.

TRANSLATIONAL STROKE RESEARCH (2010)

Add to Collection

Review Immunology

Exploring the full spectrum of macrophage activation

David M. Mosser et al.

NATURE REVIEWS IMMUNOLOGY (2008)

Add to Collection

Article Cell Biology

Pivotal advance: Activation of cell surface Toll-like receptors causes shedding of the hemoglobin scavenger receptor CD163

Lehn K. Weaver et al.

JOURNAL OF LEUKOCYTE BIOLOGY (2006)

Add to Collection

Article Neurosciences

CD163-positive perivascular macrophages in the human CNS express molecules for antigen recognition and presentation

BO Fabriek et al.

GLIA (2005)

Add to Collection

Article Gastroenterology & Hepatology

Soluble CD163 in patients with liver diseases: very high levels of soluble CD163 in patients with fulminant hepatic failure

A Hiraoka et al.

JOURNAL OF GASTROENTEROLOGY (2005)

Add to Collection

Review Neurosciences

Regeneration beyond the glial scar

J Silver et al.

NATURE REVIEWS NEUROSCIENCE (2004)

Add to Collection

Article Hematology

Plasma level of the macrophage-derived soluble CD163 is increased and positively correlates with severity in Gaucher's disease

HJ Moller et al.

EUROPEAN JOURNAL OF HAEMATOLOGY (2004)

Add to Collection

Article Neurosciences

Matrix metalloproteinases in neuroinflammation

GA Rosenberg

GLIA (2002)

Add to Collection

Article Hematology

Human natural killer cells:: a unique innate immunoregulatory role for the CD56bright subset

MA Cooper et al.

BLOOD (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.